R

Repligen Corp
D

RGEN

144.570
USD
-2.05
(-1.39%)
Market Closed
Volume
34,541
EPS
1
Div Yield
-
P/E
-4,819
Market Cap
8,099,783,633
OverviewSignalsIdeasNews
Related Instruments
    A
    ALLO
    0.03500
    (1.91%)
    1.87000 USD
    A
    ARCT
    0.680
    (4.59%)
    15.500 USD
    A
    ARWR
    -0.020
    (-0.10%)
    19.450 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    F
    FATE
    0.04000
    (2.42%)
    1.69000 USD
    N
    NSTG
    0
    (0%)
    0.000000 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    V
    VCYT
    1.840
    (4.71%)
    40.900 USD
    More
News

Title: Repligen Corp

Sector: Healthcare
Industry: Medical Instruments & Supplies
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.